title: [Inhaled therapies for cystic fibrosis].
abstract: Inhaled therapies play a significant role in the management of cystic fibrosis patients. Mucolytic and airway-rehydrating agents improve mucociliary clearance and respiratory functional status. Nebulized antibiotherapy achieve high local concentration, while reducing systemic toxicity. Tolerance to inhaled treatments is good excepting frequent bronchoconstriction which can usually be prevented by prior administration of beta2-mimetics. The majority of treatments are only available in liquid formulations. Thus, nebulization is the most frequently used inhalation mode. Vibrating-mesh nebulizers have significantly reduced inhalation time.
authors.affiliation: Service de pneumologie, Département de médecine, CHUV, 1011 Lausanne. Samir.Lahzami@chuv.ch
authors.forename: Samir
authors.initials: S
authors.lastname: Lahzami
authors.forename: Laurent P
authors.initials: LP
authors.lastname: Nicod
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001993:Bronchodilator Agents / Q000008:administration & dosage; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000628:therapy*; D003850:Deoxyribonuclease I / Q000008:administration & dosage; D006801:Humans; D009079:Mucociliary Clearance / Q000187:drug effects; D009330:Nebulizers and Vaporizers; D012138:Respiratory Therapy / Q000379:methods* / Q000639:trends; D012462:Saline Solution, Hypertonic / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D012462:Saline Solution, Hypertonic; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I